PCV7: CROSS-CULTURAL ADAPTATION OF THE SEATTLE ANGINA QUESTIONNAIRE (SAQ) IN I I COUNTRIES  by Conway, K et al.
26 Abstracts
OBJECTIVE: Quality of life is not well studied in atrial
fibrillation (AF), the most prevalent rhythm disturbance
with significant impact on morbidity and mortality. We
report the development of a brief disease-specific QoL in-
strument for use in clinical trials, surveillance studies, and
clinical practice.
METHODS: Fifty-one items, based on literature, patient
focus groups, and a cardiology expert panel were admin-
istered via telephone interview to 73 chronic AF and 23
congestive heart failure (CHF), along with 25 angina con-
trol patients. 
RESULTS: Item reduction techniques produced the 20-item
AFIS comprising four symptom scales (dyspnea, fatigue, pal-
pitations syncope: 11 items) and three QoL scores measur-
ing functional, social and emotional impact (9 items). Inter-
nal consistencies were acceptable for all symptom scales
(Cronbach  0.73–0.77) and the QoL scales (Cronbach 
0.74–0.92). AFIS Total Symptom Impact (SI) score ex-
plained 50% of the variation in each QoL impact score
(R2  0.49 [functional], 0.44 [emotional], 0.55 [social]) and
75% (R2  0.74) of the total QoL impact (QI) score. We
identified two symptom impact (SI) threshold scores: mod-
erate AF impact (SI  40; sensitivity 0.86, 1-specificity 0.92)
and major AF impact (SI  60; sensitivity 0.96, 1-specificity
0.98). Mild symptomatic CAF patients (SI  40) reported
little QoL interference. Moderate symptomatic and major
symptomatic CAF patients had QI scores 200% and 665%
worse than the mild CAF patients. SI scores accounted for
50% (R2  0.50) and nearly 25% (R2  0.22) of total QI
variation in CHF and angina patients, respectively.
CONCLUSION: Mild AF symptoms are well tolerated.
However, moderate symptom impact (over 50% of pa-
tients) doubles the interference with QoL; while major
impact (33% of patients) approached a seven-fold wors-
ening of QoL. The Atrial Fibrillation Impact Scale ap-
pears to be a useful tool for predicting worsening QoL
among atrial fibrillation patients and for informing treat-
ment decisions.
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OBJECTIVE: With the increase of QoL assessment in
clinical trials, it is necessary to have cross-culturally valid
instruments to pool data across countries.
METHODS: The SAQ, a 19-item instrument designed in
US English, assesses five domains of coronary artery dis-
ease. Prior to use in an international trial, the original
had to undergo cultural adaptation, giving rise to 11 lan-
guage versions and a modified original. The cultural ad-
aptation process involved the recruitment of a QoL spe-
cialist in each country. Native speakers produced two
independent forward translations. These were reconciled
and back-translated into English. The translations were
tested for comprehension in a sample target population,
compared and internationally harmonized. The developer
of the SAQ clarified concepts underlying each item.
RESULTS: Translation problems involved finding con-
ceptual equivalents of typical US expressions and con-
structions and translating the original response catego-
ries. Examples for which a rationale of translation choice
and modification to the original will be discussed, are the
following: although activities such as “showering” and
“swimming” are less common outside the US, satisfac-
tory equivalents were found. The translation of “how sat-
isfied are you that everything is being done. . .,” however,
had to be rendered as “how convinced are you. . . .” It
was impossible to reproduce the original response scale
referring to “very, moderately, somewhat, a little, not at
all.” Equivalent answers in the translation had to refer to
“extremely, quite a bit, moderately, slightly, not at all.”
For reasons of comparability, the original was changed
accordingly. 
CONCLUSIONS: Before use in an international trial, rig-
orous cultural adaptation was essential to producing
cross-culturally valid language versions of the SAQ. This
process, entailing modifications to an already validated
original, might make further validation necessary. Fur-
ther responsiveness data will be generated by the clinical
trial. Ideally, initial instrument design should include in-
ternational input.
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OBJECTIVES: An analysis is being carried out to assess
the impact of clinical parameters, over and above the
treatment effect, in an evaluation of coronary heart dis-
ease (CHD) in German males.
METHODS: This analysis is part of a study which uses the
Coronary Heart Disease Risk Assessment Model (CHD
RAM), a decision analytical model, to evaluate the cost-
effectiveness of cholesterol-lowering agents for the primary
prevention of CHD in German males. Although the wider
study considers data for men in eight 5-year age groups
ranging from 35–39 to 70–74 years, the clinical sensitivity
analysis focuses on the 50–55 age group for three doses of
cerivastatin, a cholesterol-lowering agent. Baseline data
were primarily obtained from the published literature and
expert opinion. The clinical parameters—compliance rate
profiles, smoking behaviour, mean body mass index and
systolic blood pressure—will be assessed in terms of their
impact on CHD risk and life years gained. This will be esti-
